about
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial.Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responsesMIG and the regulatory cytokines IL-10 and TGF-β1 correlate with malaria vaccine immunogenicity and efficacy.Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus AnkaraEarly gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naïve and malaria-exposed individuals.Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area.A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria.The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming.Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.High production of pro-inflammatory cytokines by maternal blood mononuclear cells is associated with reduced maternal malaria but increased cord blood infection.Correction: Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium bergheiPrime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+T-Cell Responses
P50
Q33317265-0840058A-B2C1-4A9B-8C68-EF661B135448Q33557760-77949CF6-6C54-4B0E-86CA-E788C55F22ABQ33691320-7D565871-A404-41BB-997B-BAB09388448CQ33935092-BFF560A9-4860-4EA8-96C2-67AF42864A64Q35217534-897E7665-C791-41A1-A230-5333F96A6BA8Q36092323-9E0CEF46-163D-4092-9D05-DE3A29648B4FQ36252595-0587C659-D7F8-4FA5-9F63-D45FB8CB808CQ37331599-666B8D7B-1DEB-40CA-AFF2-1E0E09DD4AB5Q38979606-0051CA73-F9C6-4C72-9D77-3D8D7AD1D5E6Q39125907-88189E12-7A51-46EE-9F6D-108562C405CFQ39527145-5491121D-7FB0-4434-9D5B-5D30CB1177B8Q39566146-82B20759-08FC-410D-AB0D-3B40A285CF8CQ39571550-3D888C93-57CC-49F4-80CB-3D191D5CC16CQ39571564-859E2532-BD2F-49CE-9329-53FC9A57D96AQ40125164-A0E073DA-BD8C-4A66-B2F2-102253D1D506Q53819703-8983A929-144C-44B3-A800-B1309AEC1C9DQ56774438-F8C865B4-A25C-45BE-8AF5-66E80294AFF5Q56774449-61C90C17-B999-4CB8-A9C9-602D2E1EFD54
P50
name
Tamara Berthoud
@en
type
label
Tamara Berthoud
@en
prefLabel
Tamara Berthoud
@en